Alnylam Pharmaceuticals Inc logo

ALNY - Alnylam Pharmaceuticals Inc Share Price

$135.7 2.8  2.1%

Last Trade - 14/05/21

Large Cap
Market Cap £11.12bn
Enterprise Value £10.04bn
Revenue £406.4m
Position in Universe 706th / 6849
Unlock ALNY Revenue
Relative Strength (%)
1m -0.95%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
41.1 47.2 89.9 74.9 219.8 492.9 838.5 1,297 +64.4%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AlnylamPharmaceuticals, Inc. revenues increased 79% to $177.6M.Net loss increased 10% to $200.3M. Revenues reflectONPATTRO segment increase from $5.3M to $102M, UnitedStates segment increase of 79% to $125.1M, Europe segmentincrease of 92% to $40.7M. Higher net loss reflectsNon-Cash Stock Based Compansation increase of 69% to $31.3M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ALNY
Graphical History


ALNY Revenue Unlock ALNY Revenue

Net Income

ALNY Net Income Unlock ALNY Revenue

Normalised EPS

ALNY Normalised EPS Unlock ALNY Revenue

PE Ratio Range

ALNY PE Ratio Range Unlock ALNY Revenue

Dividend Yield Range

ALNY Dividend Yield Range Unlock ALNY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ALNY EPS Forecasts Unlock ALNY Revenue
Profile Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated May 8, 2003
Public Since May 28, 2004
No. of Shareholders: 27
No. of Employees: 1,453
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 117,545,040
Free Float (0.0%)
Eligible for
ALNY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ALNY
Upcoming Events for ALNY
Tuesday 18th May, 2021
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
Tuesday 25th May, 2021
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference
Wednesday 4th August, 2021 Estimate
Q2 2021 Alnylam Pharmaceuticals Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Alnylam Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Alnylam Pharmaceuticals Inc
What is the Alnylam Pharmaceuticals Inc share price?

As of 14/05/21, shares in Alnylam Pharmaceuticals Inc are trading at $135.7, giving the company a market capitalisation of £11.12bn. This share price information is delayed by 15 minutes.

How has the Alnylam Pharmaceuticals Inc share price performed this year?

Shares in Alnylam Pharmaceuticals Inc are currently trading at $135.7 and the price has moved by -4.69% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alnylam Pharmaceuticals Inc price has moved by -33.09% over the past year.

What are the analyst and broker recommendations for Alnylam Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Alnylam Pharmaceuticals Inc, there are there are currently 3 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alnylam Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Alnylam Pharmaceuticals Inc next release its financial results?

Alnylam Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Alnylam Pharmaceuticals Inc dividend yield?

Alnylam Pharmaceuticals Inc does not currently pay a dividend.

Does Alnylam Pharmaceuticals Inc pay a dividend?

Alnylam Pharmaceuticals Inc does not currently pay a dividend.

When does Alnylam Pharmaceuticals Inc next pay dividends?

Alnylam Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Alnylam Pharmaceuticals Inc shares?

To buy shares in Alnylam Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Alnylam Pharmaceuticals Inc?

Shares in Alnylam Pharmaceuticals Inc are currently trading at $135.7, giving the company a market capitalisation of £11.12bn.

Where are Alnylam Pharmaceuticals Inc shares listed? Where are Alnylam Pharmaceuticals Inc shares listed?

Here are the trading details for Alnylam Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ALNY
What kind of share is Alnylam Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Alnylam Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Alnylam Pharmaceuticals Inc share price forecast 2021?

Shares in Alnylam Pharmaceuticals Inc are currently priced at $135.7. At that level they are trading at 31.49% discount to the analyst consensus target price of 0.00.

Analysts covering Alnylam Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -6.372 for the next financial year.

How can I tell whether the Alnylam Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alnylam Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -12.44%. At the current price of $135.7, shares in Alnylam Pharmaceuticals Inc are trading at -4.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Alnylam Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Alnylam Pharmaceuticals Inc.

Who are the key directors of Alnylam Pharmaceuticals Inc?

Alnylam Pharmaceuticals Inc's management team is headed by:

John Maraganore - CEO
Akshay Vaishnaw - CEX
Steven Paul - IND
Marsha Fanucci - IND
Dennis Ausiello - IND
Michael Bonney - CHM
Laurie Keating - EVP
Yvonne Greenstreet - PRE
Margaret Hamburg - IND
Jeffrey Poulton - CFO
Olivier Brandicourt - IND
Who are the major shareholders of Alnylam Pharmaceuticals Inc?

Here are the top five shareholders of Alnylam Pharmaceuticals Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 13.47% (15.8m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.96% (10.5m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 8.57% (10.1m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 8.56% (10.1m shares)
Vanguard Health Care Fund Mutual Fund
Percentage owned: 6.52% (7.67m shares)
Similar to ALNY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.